HISTORY

2024

  • 01Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in pancreatic cancer

2023

  • 11Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of Acute Radiation Syndrome (ARS)
  • 05NIT-A01(Acute Radiation Syndrome), Commencement of preclinical trial in rodent
  • 03NIT-112(Large B-cell lymphoma(LBCL)), Protocol change of clinical trial obtained FDA approval

2022

  • 12Signed contract with National Institute of Allergy and Infectious Diseases (NIAID) to develop Acute Radiation Syndrome (ARS)
  • 07Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of glioblastoma multiforme

2021

  • 06NIT-108(Kaposi Sarcoma) Phase 1 clinical trial IND approved by FDA
  • 03Listed on the KOSDAQ
  • 01NIT-113 (Progressive Multifocal Leukoencephalopathy, PML) Clinical trial IND approved by FDA

2020

  • 10Announced a clinical collaboration with Roche for TECENTRIQ® (atezolizumab)/NT-I7 combination targeting non-small cell lung cancer (NSCLC)
    NIT-119(NSCLC 1L) Phase 2 clinical trial IND approved by FDA
  • 08NIT-112(Large B-cell lymphoma), Phase 1b clinical trial IND approved by FDA
  • 06Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of Progressive Multifocal Leukoencephalopathy (PML)
  • 04Announced a clinical collaboration with Bristol Myers Squibb (BMS) for OPDIVO® (nivolumab)/ NT-I7 combination targeting gastric cancers
  • 01NIT-110 (TNBC, NSCLC, SCLC, PC, MSS-CRC, Ovarian cancer) Phase 1b/2a clinical trial approved by FDA

2019

  • 12Announced a clinical collaboration with Merck for KEYTRUDA® (pembrolizumab)/ NT-I7 combination targeting solid tumors
  • 08NeoImmuneTech Co., Ltd., a wholly owned subsidiary of NIT, was established
  • 04Granted Orphan Drug Designation (ODD) from FDA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia (ICL)

2018

  • 05Established liaison office in Korea
  • 04Announced a clinical trial collaboration with Roche for TECENTRIQ® (atezolizumab)/ NT-I7 combination targeting advanced high-risk skin cancers

2017

  • 10Headquarters relocated and expanded to 2400 Research Boulevard, Rockville, MD 20850
  • 05Granted Orphan Drug Designation (ODD) from EMA for NT-I7 in the treatment of Idiopathic CD4 lymphocytopenia (ICL)

2015

  • 06Received development and commercialization rights of NT-I7 (efineptakin alfa, rhIL-7-hyFc) from Genexine in America and Europe

2014

  • 10Headquarters relocated to 2200 Research Blvd., Rockville, MD 20850
  • 01NeoImmuneTech, Inc. Founded at 20271 Goldenrod Lane Germantown, MD 20876